IP Library Granted Patent US 10,898,613
Granted Patent B2
US 10,898,613 · App. 16/335,093 · Granted Jan 26, 2021

Hyaluronic acid gel with a divalent zinc cation

Inventors: Laura Jing Jing (Antibes, FR); Craig Steven Harris (Biot, FR); Anders Karlsson (Storvreta, SE); Elin Säwén (Sollentuna, SE)
Assignee: NESTLÉ SKIN HEALTH SA
A61L27/52A61L27/025A61L27/20A61L27/54A61L27/58A61L2300/102A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,613
App. No.
16/335,093
Granted
Jan 26, 2021
Kind
B2
Abstract

A method of preparing a sterilized injectable hydrogel composition, including the steps: a) covalently crosslinking a glycosaminoglycan using a bi- or polyfunctional crosslinking agent to form a covalently crosslinked glycosaminoglycan, b) swelling the covalently crosslinked glycosaminoglycan in a solution including a divalent cation to form a hydrogel composition, and c) sterilizing the hydrogel composition by autoclaving to form a sterilized injectable hydrogel composition, and to sterilized injectable hydrogel compositions obtainable by such method.

Claims (26)

1. A sterilized injectable hydrogel composition, comprising:

(i) a covalently crosslinked glycosaminoglycan, wherein the glycosaminoglycan is hyaluronic acid, and

(ii) a divalent cation, wherein the divalent cation is Zn 2+ , and wherein the concentration of Zn 2+ in the composition is in the range of 0.5 to 2 mM;

wherein the composition releases the divalent cation at a rate below 0.1 mmol/day upon injection into a subject, and

wherein the composition has been subjected to sterilization by autoclaving.

2. The composition according to claim 1 , wherein the concentration of the divalent cation in the composition is in the range of 0.8 to 2 mM.

3. The composition according to claim 2 , wherein the concentration of Zn 2+ in the composition is in the range of 0.8 to 1.5 mM.

4. The composition according to claim 3 , wherein the concentration of Zn 2+ in the composition is about 1.0 mM.

5. The composition according to claim 1 , further comprising a therapeutically relevant concentration of a local anesthetic selected from the group consisting of lidocaine and ropivacaine.

6. The composition according to claim 1 , wherein the composition exhibits increased stability compared to an identical composition without the divalent cation.

7. A method of preparing a sterilized injectable hydrogel composition comprising:

(i) a covalently crosslinked glycosaminoglycan, wherein the glycosaminoglycan is hyaluronic acid, and

(ii) a divalent cation, wherein the divalent cation is Zn 2+ , and the concentration of Zn 2+ in the composition is in the range of 0.5 to 2 mM;

wherein the composition releases the divalent cation at a rate below 0.1 mmol/day upon injection into a subject, the method comprising:

(a) covalently crosslinking a glycosaminoglycan using a bi- or polyfunctional crosslinking agent to form a covalently crosslinked glycosaminoglycan, wherein the glycosaminoglycan is hyaluronic acid, and

(b) swelling the covalently crosslinked glycosaminoglycan in a solution comprising Zn2+, to form a hydrogel composition, wherein the concentration of Zn2+ in the solution is in the range of 0.5 to 2 mM; and

(c) sterilizing the hydrogel composition by autoclaving to form the sterilized injectable hydrogel composition.

8. The method according to claim 7 , wherein the concentration of Zn 2+ in the solution is in the range of 0.8 to 2 mM.

9. The method according to claim 8 , wherein the concentration of Zn 2+ in the solution is in the range of 0.8 to 1.5 mM.

10. The method according to claim 8 , wherein the concentration of Zn 2+ in the solution is about 1.0 mM.

11. The method according to claim 7 , wherein the solution further comprises a therapeutically relevant concentration of a local anesthetic selected from the group consisting of lidocaine and ropivacaine.

12. The method according to claim 7 , wherein the sterilized injectable hydrogel composition exhibits increased stability compared to an identical composition without the divalent cation.

13. A method of cosmetically treating skin, the method comprising administering to the skin the sterilized injectable hydrogel composition according to claim 1 .

14. The composition according to claim 1 , wherein the glycosaminoglycan is in the range of 5 to 30 mg/mL.

15. The composition according to claim 1 , wherein the divalent cation is added as a zinc salt.

16. The composition according to claim 15 , wherein the zinc salt is selected from zinc chloride, zinc gluconate, or zinc citrate.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Dec 31, 2020
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 054899/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2019
From: JING, LAURA JING; HARRIS, CRAIG STEVEN; KARLSSON, ANDERS; SÄWÉN, ELIN
To: NESTLÉ SKIN HEALTH SA
Reel/Frame 049180/0711 →